Adverum Climbs Out Of Abyss With Promising Early Gene Therapy Data In Wet AMD

The Phase II LUNA study of ixo-vec showed a reduction in anti-VEGF use and stabilization of visual acuity and anatomic parameters that Adverum – and some analysts – called best in class.